Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perspective Therapeutics ( (CATX) ) has issued an announcement.
On March 16, 2026, Perspective Therapeutics reported full-year 2025 results and recent business highlights, underscoring progress across all three clinical-stage radiopharmaceutical programs and strengthening its financial position. Updated data for lead asset VMT-α-NET in neuroendocrine tumors showed favorable tolerability, absence of dose-limiting toxicities, durable disease control and deepening tumor responses, with Cohort 2 and Cohort 3 follow-up expected to support regulatory discussions and broader conference presentations in 2026.
The company also advanced VMT01 in heavily pre-treated melanoma at a 3.0 mCi dose, both as monotherapy and in combination with nivolumab, and expanded early clinical work on FAP-α–targeting PSV359, while preparing additional preclinical constructs for potential first-in-human imaging. Perspective ended 2025 with approximately $145 million in cash, cash equivalents and short-term investments and subsequently raised about $164 million in an equity offering, which it expects will fund planned clinical milestones and operational investments into late 2027, supporting continued pipeline and manufacturing expansion.
The most recent analyst rating on (CATX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held down primarily by very weak profitability and significant cash burn despite a low-debt balance sheet. Technicals are currently strong with price well above key moving averages, but elevated RSI suggests overbought risk. Recent financing and positive pipeline updates provide a supportive backdrop, while valuation is difficult to support given ongoing losses and no indicated dividend yield.
To see Spark’s full report on CATX stock, click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on pioneering advanced targeted radiopharmaceutical treatments for cancers throughout the body. Its pipeline includes VMT-α-NET for somatostatin receptor-positive neuroendocrine tumors, VMT01 for MC1R-positive melanoma, and PSV359 targeting fibroblast activation protein-α in multiple solid tumors.
Average Trading Volume: 3,400,115
Technical Sentiment Signal: Buy
Current Market Cap: $569.6M
For a thorough assessment of CATX stock, go to TipRanks’ Stock Analysis page.